In a patient on antiretroviral therapy who develops a maculopapular rash, how should a seroconversion rash be distinguished from a drug‑induced rash and what is the appropriate management?

Distinguishing Seroconversion Rash from Drug-Induced Rash in HIV Patients on ART

In a patient on antiretroviral therapy who develops a maculopapular rash, this is almost certainly a drug-induced hypersensitivity reaction rather than a seroconversion rash, because seroconversion rash occurs during acute HIV infection (before ART initiation), not during established treatment.

Key Distinguishing Features

Timing is Critical

• Seroconversion rash occurs 2-4 weeks after initial HIV exposure, during acute retroviral syndrome, when the patient is HIV-antibody negative or just turning positive—this happens before any ART is started
• Drug-induced rash typically appears 1-6 weeks after starting the offending antiretroviral medication 1
• Any rash occurring more than 3 months after starting ART is almost always due to another cause, not the antiretroviral 1

Clinical Context

If your patient is already on ART, they are by definition past the seroconversion window. The diagnostic question becomes: which antiretroviral is causing the reaction?

Drug-Specific Rash Patterns and Frequencies

High-Risk Antiretrovirals

NNRTIs (Non-Nucleoside Reverse Transcriptase Inhibitors):

• Nevirapine: 17-32% rash incidence, with 2-10% requiring discontinuation 1
• Efavirenz: 4.6-20% rash incidence 1
• Etravirine: 16% rash incidence, 2% discontinuation 1

Abacavir (NRTI):

• 2.3-9% hypersensitivity reaction rate 1
• Strongly associated with HLA-B*5701 (100% sensitivity in both White and Black patients) 1
• Should have been screened before prescription

Protease Inhibitors:

• Darunavir: 6.7% rash incidence 1
• Tipranavir: 2-14% rash incidence 1
• Lopinavir/ritonavir: 2-4% rash incidence 1

Management Algorithm

Step 1: Assess Severity Immediately

Mild-to-moderate maculopapular rash WITHOUT systemic symptoms:

• Erythematous, maculopapular, widespread 1
• No fever, no mucosal involvement, no internal organ symptoms
• Action: Can treat through the rash with close monitoring 1

Severe reactions requiring immediate ART discontinuation:

• DRESS syndrome (Drug Rash with Eosinophilia and Systemic Symptoms): fever, hepatitis, eosinophilia 1
• Stevens-Johnson Syndrome/TEN: blistering, mucosal involvement (mouth ulcers, conjunctivitis), >10% body surface area involvement 1
• Constitutional symptoms: fever, rigors, myalgias, arthralgias 1
• Internal organ involvement: hepatitis (elevated LFTs), pneumonitis, nephritis 1

Step 2: Laboratory Evaluation

Essential tests:

• Complete blood count with differential (look for eosinophilia) 1
• Liver function tests (hepatotoxicity common with nevirapine, efavirenz) 1
• Renal function
• CD4 count (higher CD4 counts associated with increased nevirapine hypersensitivity) 1

Histopathology if diagnosis unclear 2:

• Drug exanthem favored by: moderate spongiosis, extensive basal cell damage, multiple necrotic keratinocytes, eosinophil-rich infiltrate
• Viral etiology favored by: cytopathic changes, lymphocytic vasculitis

Step 3: Identify the Culprit Drug

Review timing:

• Which drug was started most recently (within 1-6 weeks)? 1
• NNRTIs and abacavir are the most common culprits

If abacavir suspected:

• Check HLA-B*5701 status (should have been done pre-prescription) 1
• Never rechallenge—can be fatal 1

If NNRTI suspected:

• Nevirapine most likely, especially if CD4 >250 cells/mm³ in women or >400 cells/mm³ in men 1

Step 4: Management Based on Severity

For mild-to-moderate rash:

• Continue ART with close monitoring (2-3 times weekly initially) 1
• Symptomatic treatment: antihistamines, topical corticosteroids
• If rash worsens or systemic symptoms develop, stop the offending drug immediately

For severe reactions or DRESS/SJS/TEN:

• Stop all antiretrovirals immediately 1
• Hospitalize for supportive care
• Systemic corticosteroids may be needed for DRESS
• Consult dermatology

For confirmed drug hypersensitivity:

• Switch to alternative regimen avoiding the drug class if possible 3
• Document allergy clearly in medical record
• Never rechallenge with the same drug 1

Step 5: Switching Regimens

After identifying culprit drug 3:

• Review resistance testing history before switching
• If NNRTI caused reaction: switch to integrase inhibitor-based regimen (dolutegravir + 2 NRTIs)
• If abacavir caused reaction: switch to tenofovir alafenamide or tenofovir disoproxil fumarate + emtricitabine
• Check viral load 1 month after switching 3

Critical Pitfalls to Avoid

1. Do not rechallenge with suspected drug—reactions are more rapid and severe on re-exposure 1
2. Do not assume viral etiology in a patient already on ART—seroconversion has already occurred
3. Do not ignore mild rash—monitor closely as it can progress to severe reactions
4. Do not forget HLA-B*5701 testing before prescribing abacavir (mandatory or recommended in most countries) 1
5. Do not continue drug if systemic symptoms, fever, mucosal involvement, or elevated LFTs develop 1